Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Lectins Stories

2014-03-04 08:31:20

-- Successful Phase 1 Results Set the Stage for Trials in Patients with Life-Threatening Blood Disorders -- SEATTLE, March 4, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin?associated serine protease-2 (MASP-2), the...

2013-11-05 08:34:01

-- Ongoing Clinical Program for OMS721 Continues to Advance -- SEATTLE, Nov. 5, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in a well-established animal model of neovascular age-related macular degeneration (AMD), which is characterized by abnormal growth of new blood vessels behind the retina of the eye and is a...

2013-10-31 08:32:49

PRINCETON, N.J., Oct. 31, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today submission of a full contract proposal to the National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases. Successful...

2013-08-19 08:27:55

SANTA ROSA, Calif., Aug. 19, 2013 /PRNewswire/ --A groundbreaking peer reviewed case report by Dr. Isaac Eliaz, M.D. of Amitabha Medical Clinic, demonstrates for the first time the clinical use of novel biomarker galectin-3 to assess cancer progression and inflammation. The case study titled, "The Role of Galectin-3 as a Marker of Cancer and Inflammation in a Stage IV Ovarian Cancer Patient with Underlying Pro-Inflammatory Comorbidities," was published in the July 2013 issue of Case...

2013-06-13 08:27:27

-- Enrollment Expected to Begin Next Month -- SEATTLE, June 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program. The first clinical trial with OMS721 will be conducted in Europe and will evaluate the safety, tolerability, pharmacodynamics and...

2013-06-11 16:26:13

Department of Homeland Security study conclusively demonstrates that the Tetracore Ricin BioThreat Alert® Lateral Flow Assay is a robust assay that can be used to rapidly screen for the presence of Ricin in an environmental sample. ROCKVILLE, Md., June 11, 2013 /PRNewswire-USNewswire/ -- Tetracore Inc., a biotechnology company, announces the successful completion of an extensive study of its Ricin BioThreat Alert Lateral Flow Assay (LFA) and BioThreat Alert LFA Reader by the...

2013-05-28 08:27:55

-- Phase 1 Clinical Trial Expected to Begin Early Next Quarter -- SEATTLE, Wash., May 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a Clinical Trial Application (CTA) with European regulators to initiate clinical trials evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program. The lead indication for OMS721 will be atypical hemolytic uremic syndrome...

2013-05-23 08:28:46

ATLANTA, May 23, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the Company's Annual Meeting of Shareholders. Due to technological difficulties, a different phone number than previously circulated will be used for accessing the call. The audio portion of the call can now be accessed by dialing (888) 582-3528 (toll-free within the United States) or (847) 944-7361...

2013-05-22 12:30:23

Study shows lectins have negative effect on health, but stops short of looking at blood-type specific lectins. BRIDGEPORT, Conn., May 22, 2013 /PRNewswire/ -- A study presented at the American Heart Association's 2013 Scientific Session found that a diet high in lectins, a carbohydrate binding protein, can be detrimental to your health. Lectins are commonly found in grains, legumes, tomatoes, and vegetables belonging to the nightshade family. The research found that the lectins in...

2013-05-15 08:30:19

ATLANTA, May 15, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the Company's Annual Meeting of Shareholders. Additionally, Peter Traber, MD, President, CEO and CMO of Galectin Therapeutics, will update the investment community on the Company's pipeline of galectin inhibitor compounds and progress in its development of treatments for liver fibrosis and cancer. Following...